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a b s t r a c t
The reaction between the high-dose drug substance 5-aminosalicylic acid (5-ASA) and the excipient
citric acid during storage of an experimental enema preparation has been studied and three isobaric
reaction products, i.e., an ester and an amide with non-symmetrically substituted citric acid moieties and
a symmetrical amide, were identiﬁed by combined use of HPLC–SPE–NMR and HPLC–MS. After storage
for 1 week at 70 ◦C, approximately 5% of the 5-ASA present in the formulation was transformed into these
impurities. Storage of the enema for 32 months at room temperature led to loss of approximately 10% of
the original amount of 5-ASA, with the ester as the main reaction product.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
The development of methods based on hyphenation of sep-
aration techniques and nuclear magnetic resonance (NMR) have
greatly improved possibilities of identiﬁcation of mixture com-
ponents without the need of prior isolation and puriﬁcation of
individual compounds [1]. Thus, in contrast to well-established
HPLC–MS methods, which are characterised by speed and high
sensitivity but also by limited information content with respect
to details of molecular structure, HPLC–NMR allows unambiguous
on-line identiﬁcation of even very complex structures. A recent
extension of the original HPLC–NMR repertoire of experiments
(comprising on-ﬂow, stopped ﬂow and loop-storage techniques
[1,2]) is HPLC–SPE–NMR, where the analytes are separated from
the HPLC mobile phase by means of post-column solid-phase
extraction and then submitted, in an automated fashion, to NMR
measurements in a deuterated solvent. Combined advantages of
analyte focusing, accumulation by multiple SPE collections and
the use of deuterated solvents makes HPLC–SPE–NMR capable of
providing NMR data of higher quality than what is usually achiev-
able by direct HPLC–NMR methods, i.e., methods where NMR
∗ Corresponding author. Tel.: +45 35336463.
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data are obtained with analytes dissolved in the HPLC mobile
phase [2–4]. However, the HPLC–SPE–NMR technique is inherently
dependent on the effectiveness of the post-column SPE process
[5]. The HPLC–SPE–NMR technique is becoming increasingly popu-
lar, especially in natural products research [6–10], food and food
supplement analysis [11,12], and pharmaceutical analysis [13],
including analysis of drug degradation [14] and drug metabolism
[15,16]. In this work, we describe the ﬁrst example of application of
HPLC–SPE–NMR to analysis of reaction products formed by inter-
actions between a drug substance and an excipient upon storage of
a pharmaceutical formulation.
For more than half a century, 5-aminosalicylic acid (5-ASA) has
been used in the treatment of chronic inﬂammatory bowel dis-
eases, originally in the form of the prodrug sulphasalazine [17] and
subsequently as 5-ASA itself, and in the beginning of the 1980’s
the development of 5-ASA drugs accelerated [18–20]. Enemas are
among the popular formulation forms for colonal delivery and are
still very important in the treatment of distal colitis and procti-
tis [21,22]. The present text deals with the formation of impurities
in an enema formulation of 5-ASA, that has been under develop-
ment by a pharmaceutical company. It was important to elucidate
the structures of the impurities in order to eliminate them from
the ﬁnal formulation. 5-ASA is used in relatively large doses and
therefore has a potential of formation of relatively high amounts of
potentially harmful impurities.
0731-7085/$ – see front matter © 2008 Elsevier B.V. All rights reserved.
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Because 5-ASA is prone to oxidation, especially in alkaline solu-
tion, a number of excipients are usually added to 5-ASA solutions,
including ethylenediaminetetraacetic acid, sulﬁte, and citric acid.
The latter iswidely used in pharmaceutical formulations as an acid-
iﬁer, complexing agent or buffer substance. However, citric acid
and other di- and polycarboxylic acids can form cyclic anhydrides,
which can signiﬁcantly increase their reactivity in the liquid as well
as the solid state [23–25]. Recently, a reaction between 5-ASA and
citric acid in a formulation produced by hot-melt technology has
been reported, but no ﬁnal conclusion about the structure of the
reaction product was reached [26].
In high dose-drugs, an impurity present in an amount of 0.1%
or more relative to the active substance has to be conclusively
identiﬁed. This identiﬁcation threshold often poses a considerable
analytical challenge. Here, we describe identiﬁcation of reaction
products formed in liquid formulations from 5-ASA and citric acid
using HPLC–SPE–NMR supported by HPLC–MS. The study thus
addresses the problem of distinction between isomeric products
formed with this widely used pharmaceutical excipient and is of
potential interest for product control of liquid pharmaceutical for-
mulations of drugs containing hydroxy and amino groups.
2. Experimental
2.1. Materials
Citric acid monohydrate and formic acid were purchased
from Sigma–Aldrich Chemie (Steinhem, Germany). Methanol and
phosphoric acid were purchased from VWR (Leicester, England).
5-Aminosalicylic acid (5-ASA) and N-acetyl-5-aminosalicylic acid
were obtained from Ferring Pharmaceuticals (Copenhagen, Den-
mark).
2.2. High-performance liquid chromatography–mass
spectrometry (HPLC–MS)
HPLC–MS experiments were performed on an Agilent 1100
HPLC/MSD system (Agilent Technologies, Palo Alto, CA, USA).
The chromatographic system consisted of a Phenomenex Luna
2×100mm 3m C18 column kept at 40 ◦C and the mobile phases A
(10%MeOHinwater, added0.1%HCOOH)andB (90%MeOHinwater,
added 0.1% HCOOH). The gradient elution proﬁle was 0% B at 0min,
20% B at 10min, 50% B at 20 to 24min, 0% B at 24.1min, with a ﬂow-
rate of 0.3mL/min and a total runtime of 42min. UV traces were
recorded at 240nm. The MSD was used in positive electrospray
mode, drying gas ﬂow 12L/min, nebuliser pressure 40psi, drying
gas temperature 350 ◦C, capillary voltage 4kV and fragmentor 80V.
The MSD was programmed to scan from 100–1200a.m.u. with a
cycle timeof 1.08 s. Sampleswere diluted appropriatelywithwater;
the total concentration was typically 0.5mg/mL and the injection
volume was 5L.
2.3. High-performance liquid chromatography–solid-phase
extraction–nuclear magnetic resonance (HPLC–SPE–NMR)
The HPLC–SPE–NMR system consisted of an Agilent 1100 series
chromatograph (quaternary pump, autosampler, column oven,
photodiode arraydetector), a KnauerK100Wellchrompost-column
solvent delivery pump (Berlin, Germany), a Spark Prospekt 2 device
(Emmen, Holland), and a Bruker Avance 600MHz NMR spectrom-
Fig. 1. Structures of 5-ASA, citric acid, their esters and amides (1–4), and the model compound N-acetyl-5-ASA.
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Fig. 2. HPLC–UV–MS chromatograms of enema formulation containing 5-ASA and citric acid after storage for 32 months at ambient temperature. (A) UV trace at 240nm.
(B) Total ion chromatogram. (C) Extracted ion chromatogram m/z 328. (D) Extracted ion chromatogram m/z 310. Chromatographic conditions: Phenomenex Luna C18 column
eluted with a gradient of methanol in water (both containing HCOOH) with UV and positive-ion electrospray MS detection (for details, see Section 2.2).
eter (Rheinstetten, Germany) equipped with a 3mm (30L active
volume) 1H{13C} ﬂow probe. The separations were performed at
40 ◦C on a 10×150mm Phenomenex Luna 3m C18 column with a
ﬂow-rate of 0.8mL/min. The mobile phase consisted of 35% MeOH
in water with 0.1% HCOOH added. The post-column diluent was
0.1% HCOOH in water, ﬂow rate 2mL/min. Injection volume was
100L. Threshold absorbance levels for analyte trapping were
deﬁned at 240nm and six cumulative trappings on 2×10mm
HySphere C18 HD cartridges were performed. Compounds were
eluted fromtheSPEcartridgeswithmethanol-d4. The 1HNMRspec-
tra were calibrated to the residual solvent signal of methanol-d4 at
ı 3.31.
2.4. Stability of 5-ASA formulations
An enema formulation containing 5.00g 5-ASA, 0.10 g sodium
edetate, 1.00 g sodium pyrosulﬁte, 5.00 g citric acid monohydrate,
1.75 g sodium hydroxide and 490g puriﬁed water was investigated.
The pH of the suspension was 4.8. The formulation was stored for
1 week at 70 ◦C. Another sample was stored at ambient temper-
ature for 32 months. In both cases, the suspension was diluted
ten-foldwithwater beforebeing injected into theHPLC–MSsystem.
To assess stability of the reaction products towards base, 500L
of the aged preparation was mixed with 500L of 0.500M NaOH;
after5minat ambient temperatureanaliquotwasmixedwithequal
amount of 0.500M phosphoric acid, diluted four-fold with water,
and analysed immediately by HPLC–MS. A model mixture, con-
taining 100mg 5-ASA and 100mg citric acid monohydrate in 1mL
water, was heated for 3h at 70 ◦C and the supernatant analysed by
HPLC–SPE–NMR.
3. Results and discussion
In a pharmaceutical formulation containing both 5-ASA and cit-
ric acid, at least four primary reaction products1–4, i.e., two amides
(1 and 3), and two phenol esters (2 and 4), can be expected to be
formed (Fig. 1). Formation of an ester of 5-ASA with the hydroxy
group of citric acid is not expected, as tertiary alcohols do not form
esters by direct esteriﬁcation.
During a stability study of an enema formulation containing 5-
ASA as well as citric acid, formation of three new peaks (Fig. 2) was
observed by HPLC–MS (retention times 7.6, 8.3 and 10.9min), and
the same three productswere formedupon treatment of the enema
at 70 ◦C for a week. All the peaks had m/z 328, corresponding to
reaction products between 5-ASA and citric acid, although a water
loss (m/z 310) was so pronounced for the peak with retention time
8.3min that intensity of the quasimolecular ion was low (Fig. 2).
In order to elucidate structures of the reaction products, a mix-
ture of 5-ASA and citric acid was heated for 3h at 70 ◦C and the
mixture was investigated by HPLC–SPE–NMR. An HPLC–MS inves-
tigation revealed reaction products with retention times and mass
spectra identical to those formed in the real enema upon storage
at room temperature or subjected to accelerated decomposition at
70 ◦C. 1H NMR data for all three products obtained from spectra
recorded in the HPLC–SPE–NMR mode are collected in Table 1. The
spectra are shown in Fig. 3.
Table 1
1H NMR spectroscopic data (ı values with intensities, multiplicities and coupling constants in Hz in parentheses) for main reaction products between 5-ASA and citric acid,
and for authentic N-acetyl-5-aminosalisylic acid (methanol-d4).
Compound H-3 H-4 H-6 Citric acid CH2 N-acetyl CH3
1 6.90 (1H; d; 8.8) 7.62 (1H; dd; 8.8, 1.9) 8.09 (1H; d; 1.9) 2.77 (2H; d; 15.6) -
2.98 (2H; d; 15.6)
2 7.05 (1H; d; 8.8) 7.40 (1H; dd; 8.8, 2.4) 7.80 (1H; d; 2.4) 2.98 (1H; d; 16.9)
3.13 (1H; d; 16.9)
2.84 (1H; d; 18.4)
3.17 (1H; d; 18.4)
-
3 6.88 (1H; d; 8.9) 7.60 (1H; dd; 8.9, 2.1) 8.05 (1H; d; 2.1) 2.83 (1H; d; overlap)
2.97 (1H; d; 16.9)
2.83 (1H; d; overlap)
2.90 (1H; d; 14.2)
-
N-Ac-5-ASA 6.88 (1H; dd; 8.9, 0.3) 7.59 (1H; dd; 8.9, 2.7) 8.06 (1H; dd; 2.7, 0.3) - 2.10 (3H; s)
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Fig. 3. 1H NMR signals of reaction products between 5-ASA and citric acid obtained
in HPLC–SPE–NMR mode (600MHz, methanol-d4, six trappings on C18 HD SPE car-
tridges).
It is apparent that the 1H NMR spectrum recorded with the ﬁrst
of the three impurity peaks shows the presence of a symmetri-
cally substituted citric acid moiety, as the spectrum contains one
AB spin–spin coupling system with a geminal coupling constant
between the diastereotopic methylene protons. By contrast, the
spectra of the remaining compounds show the presence of two
AB systems each. The ﬁrst impurity peak can therefore be either
the amide 1 or the ester 4. The distinction between the ester and
the amide can be made on the basis of chemical shifts within the
benzene ring. Thus, comparison of the 1H NMR spectrum with
that of authentic N-acetyl-5-aminosalicylic acid (600MHz spec-
trum in methanol-d4 recorded using a 5mm tube) demonstrated,
that the chemical shifts of the benzene ring protons of the two
compounds are almost identical (Table 1). Therefore, the reaction
productwith the shortest retention time is the symmetric citric acid
amide (1).
The remaining two impurity peaks must thus correspond to
compounds 2 and 3 having non-symmetrically substituted citric
acid moiety. Again, comparison of their 1H NMR spectra with that
of N-acetyl-5-aminosalicylic acid (Table 1) demonstrated that the
major impurity is the ester 2 and the impurity with the longest
retention time is the amide 3 (cf. Fig. 2). Additional evidence was
obtained by taking advantage of the fact, that phenol esters in con-
trast to amides are very labile towards alkaline hydrolysis. Thus,
brief incubationof the agedenema formulationwith alkali followed
by acidiﬁcation led to the disappearance of themajor impurity peak
corresponding to compound 2, whereas the two minor peaks cor-
responding to compounds 1 and 3 were unchanged.
In the aged enema formulation (32 months), the amount of 5-
ASA converted to 1, 2 and 3 was approximately 1.1%, 6.6% and 1.7%,
respectively (estimated by HPLC assuming the same absorptivity of
the products at 240nm). Thus, almost 10% of the original amount
of 5-ASA was lost via the reaction with citric acid. In the accel-
erated experiment (1 week at 70 ◦C), the approximate amount of
impurities was 5%, distributed as 0.5%, 4.0%, and 0.5% of 1, 2 and 3,
respectively.
4. Conclusions
The impurity proﬁle for an enema formulation of 5-ASAwith cit-
ric acid was investigated and the impurities formed upon storage
were identiﬁed as compounds 1, 2 and 3. Formation of the sym-
metrical ester 4 was not observed, presumably because of steric
hindrance around the central carboxy group of citric acid and thus
negligible equilibrium concentration of this phenol ester. The iden-
tity of the products was established using the HPLC–SPE–NMR
technique. Use of this hyphenated technique allowed acquisition of
1H NMR data with a model formulation subjected to accelerated
decomposition, leading to identiﬁcation of the isobaric reaction
products.
Because of a relatively rapid and extensive formation of reac-
tion products between 5-ASA and citric acid, the use of citric acid
in liquid 5-ASA formulations is not recommended. Thus, based
on these ﬁndings, further development of a formulation of 5-ASA
containing citric acid was abandoned and replaced with another
formulation.
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